Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
This tool was developed based on the 2018 Diabetes Canada Clinical Practice Guidelines for the Prevention and Management of Diabetes. Published every five years, these guidelines represent the best and most current evidence-based clinical practice data for healthcare professionals.
Optimal glycemic control is fundamental to the management of diabetes. In most people with type 1 or type 2 diabetes, Diabetes Canada recommends targeting an A1c ≤7.0% to reduce the risk of vascular complications. In people with type 2 diabetes, an A1c ≤6.5% may be targeted to reduce the risk of chronic kidney disease and retinopathy, if they are assessed to be at low risk of hypoglycemia (based on class of antihyperglycemic medication(s) utilized and the person's characteristics). A higher A1c target may be considered in people with the goals of avoiding hypoglycemia and over-treatment related to antihyperglycemic therapy, with any of the following:
1. Functionally dependent: 7.1 ‐ 8.0%
2. Recurrent severe hypoglycemia and/or hypoglycemia unawareness: 7.1 ‐ 8.5%
3. Limited life expectancy: 7.1 ‐ 8.5%
4. Frail and/or with dementia: 7.1 ‐ 8.5%
5. End of life: A1c measurement not recommended. Avoid symptomatic hyperglycemia and any hypoglycemia.
References
Berard, Lori D., et al (2018). Monitoring Glycemic Control. Canadian Journal of Diabetes, vol. 42. doi:10.1016/j.jcjd.2017.10.007.
Imran, S. Ali, et al (2018). Targets for Glycemic Control. Canadian Journal of Diabetes, vol. 42. doi:10.1016/j.jcjd.2017.10.030.
Contributed By:
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email [email protected]